The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Totally agree ConsDoms,
There’s enough promise here to continue to hold, particularly at this low share price.
Junior pharma at development stage comes with plenty of risk, but the rewards can be huge. If the risk/reward ratio at these levels isn’t enough for people to stick around, they should probably never have invested here in the first place to be honest.
Like many I have a significant investment here, and I did expect HEMO to be worth way north of £100m when approved for trials. Perhaps the risk is Vlad does stick two fingers up to the London exchange.
But I remain very positive - the FDA saw enough in CAR T to allow Phase 1 trials. Phase 1 trials need to show the treatment is safe and side effects are tolerable. But I'm also expecting Phase 1 to show HEMO CAR T is effective against AML and patient(s) health improves. Just my opinion but I see enough in HEMO CAR T to stick through 2024. Best of luck holders.
Be greedy when others are fearful @dhub !
Now why would you sell your last million???? Just let it roll, if you have sole many millions previously and "only" have 1 million left, then surely you would just leave them in just in case it explodes..............very strange decision IMO
Yep all sells now are at a loss, which is a terrible shame, but many people do it the longer Vlad takes to RNS us. I do believe we will hear something a lot sooner than 6-12 months. We WILL be updated soon, I have no fear of that.
Buying at around 1.5p is suddenly becoming very tempting for me too. I’ll think about it tomorrow
You only lose out if you sell now, being down is just numbers, it’s a waiting game, could be 6 months or 12 stick with it, things are changing quickly in this field. Imagine selling then one day it goes up like a rocket, you won’t ever get over it, it will beat you up
Unfortunately for me I am down 83.4% which equates to large stack of cash. Resigned to the fact I've little choice but to stick around and see it out one way or another. Will need great results to get any form of funding in here.
You can only make a judgement for you Woodcot. In sharing your sale, at least you have allowed us to know the motivation behind it... nothing sinister can be drawn from it. All the best.
You have helped that Short @ 1.62 😆
Sorry guys the stress was too much. Just sold my last 1m of these at huge loss. Never mind.😭
Getting close to sell time I’m afraid
Jackdaw I would say technically only one and that's death, if you are savvy enough taxes can be avoided to a degree or at least the wealthy seem to be good at it.
@dhub Thank you for your reply, I don't want to loose 27% of my money and hopefully HEMO will come good. Regards my negative post in the past I apologise to all reader's. I'm just concerned as regards day by day the SP is either static or goes lower.
Re no guarantees in live wrong. There are two taxes and death
There are no guarantees in life, but I personally think the chances of a delisting is very very slim. It would have to be a last resort for Vlad, in most cases it isn't that beneficial for the company to come off the Stock Exchange either, and certainly not beneficial for us private investors. It is a gamble but if you are happy to take a 27% loss then good luck. I wouldn't be happy, and will take my chances all will be fine in the not too distant future.
Typo I'll take my 27% loss
There seems no let up regarding the SP downward spiral. My question is if HEMO delist and go private where does that leave us shareholders. Would we loose our money?
If so I'll rake my 27% loss rather than loose everything .Regards Jack.
Mrs India, of course you are right, they certainly wouldn't disclose that sort of information to a PI. The RNSs are all you can trust. It may happen, it may not happen
To state the obvious here - I'm not sure they'd disclose that kind of information to a private investor.
There wont be any breeze.. octp even writing his script for him now, vlad and just copy and paste. He can keep full control and reap most of the rewards himself stateside. Win win for him.
It may have been a thread that was deleted - not just your post.
Unsure why a chunk of comments have been deleted from yesterday. My email:
Dear Hemogenyx,
There has been informal discussions about the possibility of the company delisting from the London stock exchange. As a shareholder I am wary of rumours via the forums where these conversations take place but feel concerned due to the recent shakedown that took place by traders after the fantastic news regarding IND Trials/CBR updates.
Is there any reason to be concerned as a shareholder regarding a change in listings or privatisation of the company? I have no interest in selling you see as I think the company is going to do groundbreaking things for AML, NHL and everything else it's been working on.
Thank you for your time,
Warmest regards,
Response:
We are not aware of anything you described. Please follow official announcements.
Vladislav Sandler, Ph.D., Co-founder and CEO
Hemogenyx Pharmaceuticals LLC
760 Parkside Ave., Ste. 212, Brooklyn, NY 11226
Phone: (347) 735-8380
vladislav.sandler@hemogenyx.com
- as what I wrote yesterday has been removed for what reason I really don't get. Usually refrain from putting private emails into this forum cause it's silly but it is odd for someone to delete my very short post yesterday.
As far as the company is concerned, they don't know what people are on about regarding delisting.
Gotta wait and see what formal news comes in.
Have a good day all
Slightest breeze of news and this share takes off , Good things will come even if a take over sp would be much higher !
Stu is here. Jhfh has gone. Probs same fella. Or woman. Cant judge this day and age. 1.4s incoming. Don't like the sight of him/she/they/it
OCTP pulling out of the London Stock exchange .One of an increasing number.Kinda mitigates our CEOs struggle to get finances sorted.He was lucky to get any at all the way things are in the current market. Oxford Cannabinoid Technologies said it was delisting from London following a “continuous, irrational and regressive pressure” on its share price. The company claimed it would be much better valued as a private company and would also not have to bear the “substantial cost” of maintaining a public listing.
Clarissa Sowemimo-Coker, chief executive of Oxford Cannabinoid Technologies, said: “It has been a turbulent time on the capital markets pretty much since we listed. The last 12 to 24 months have been especially challenging for small caps and particularly in the biopharma space. Companies have lost 80pc or 90pc of their value and once you’re down there, it’s very difficult to make any inroads to start climbing back up again.”
She said this was having knock-on effects when it came to bringing new treatments to market: “Things do take longer when you’re trying to stretch for capital. You inevitably slow down drug development.”
Ms Sowmimo added: “We anticipate that as an unlisted company, a far larger pool of capital may be available to us, and therefore it is right for us to make this change.”
The British biotech, which landed a $10m (£8m) cash injection from Snoop Dogg five years ago, joined the London Stock Exchange in 2021. Since then, it has lost 97pc of its value. The company said it expected to go public again “in due course” but that it was more likely that this would be in the US.
It's irrelevant to you Stu as you are not a shareholder, just somebody who lingers around trying to unstabalise the forum...you really are pond life.